A ngiogenesis is the major feature of several retinal pathologies including proliferative diabetic retinopathy and retinopathy of prematurity (ROP). 1 In these conditions, retinal neovascularization has catastrophic effects on vision leading to hemorrhage, edema, and ultimately, blindness. 1 The factors that stimulate retinal blood vessel growth have not been fully defined, but circumstantial evidence indicates that this involves not only angiogenic cytokines such as vascular endothelial growth factor (VEGF) but also vasoactive hormones such as angiotensin II (Ang II). Recently, in a multicenter trial, the EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus (EUCLID) study group reported that ACE inhibition (ACEI) was associated with a reduction in proliferative diabetic retinopathy, 2 providing a potential clinical role for suppression of the renin-angiotensin system (RAS) in preventing and treating retinal neovascularization.
The hypothesis that an ocular RAS is involved in the development of proliferative diabetic retinopathy is supported by evidence that all components of the RAS are present in the retina [3] [4] [5] [6] [7] and that Ang II, the effector molecule of this system, is angiogenic. 8 We have localized renin to the macroglial Müller cell, 3 making this the likely site for pathophysiological processes involving the retinal RAS. The Müller cell is also the site of synthesis of the potent angiogenic factor VEGF and its tyrosine kinase receptors. 9 There is evidence of an association between VEGF, the RAS, and retinal neovascularization because both VEGF and prorenin increase in the vitreous of patients with proliferative diabetic retinopathy 10, 11 and Ang II increases VEGFR-2 receptor mRNA in retinal endothelial cells. 12 This study sought to determine if the retinal renin-angiotensin and VEGF systems influence vessel growth in a rat model of ROP and whether RAS blockade can prevent retinal neovascularization. Comparisons were made with the transgenic (mRen-2)27 rat, which exhibits enhanced renin expression in many tissues including the retina. [13] [14] [15] 
Methods

Retinopathy of Prematurity (ROP) Model
All experimental procedures adhered to the guidelines of the Australian National Health and Medical Research Council. Newborn Sprague-Dawley (SD) and homozygous transgenic Ren-2 rats and their mothers were housed in an incubator regulated at 80Ϯ2% O 2 and Ͻ2% CO 2 , with medical grade O 2 and industrial grade air. The gas composition of the chamber was monitored every 4 to 8 hours by an ML 205 gas analyzer and chart recorder (MacLab/2E System, AD Instruments Pty Ltd) while an air flow rate of Ϸ2.5L/min guarded against increases in metabolically produced CO 2 and falls in O 2 tension. The rats were housed in the incubator for 11 days. Retinal neovascularization was induced by exposure to room air for 7 days after the time in oxygen. 16 Adult homozygous Ren-2 rats are usually maintained on ACEI for blood pressure control. This drug was withdrawn from the hypertensive mothers 3 weeks before mating. All rats were allowed free access to water and standard rat chow (GR2, Clark-King & Co) and exposed to 12-hour light/dark cycles.
SD and Ren-2 rats (nϭ6 rats/group) were subjected to the following protocols: ROP shams (newborn pups housed in room air for 18 days), ROP (newborn pups housed in 80Ϯ2% O 2 for 11 days and then in room air for 7 days), and ROP rats administered either the ACEI lisinopril (Zeneca Pharmaceuticals, 10 mg/kg body wt IP daily) or the angiotensin type 1 (AT 1 ) receptor blocker losartan (Merck, 10 mg/kg body wt IP daily) from days 11 to 18. At day 18, rats were anesthetized for the collection of tissues (60 mg/kg body wt IP Nembutal, Bohringer Ingelheim).
Retinopathology and Quantification of Blood Vessels
Eyes were enucleated, fixed for 2 hours in Bouin's fixative, dehydrated in alcohol, and then embedded in paraffin for sectioning at 90°to the optic nerve. Each eye was serially sectioned at 3 m (Ϸ500 sections/eye), and every 10th section was stained with hematoxylin and eosin to examine retinal morphology. The number of blood vessel profiles (BVPs) in the inner retina were evaluated in a double-masked fashion in 3 randomly chosen sections. The inner retina comprised the inner limiting membrane (ILM), the ganglion cell layer (GCL), and the inner plexiform layer (IPL). A BVP was defined as an endothelial cell or a blood vessel with a lumen. Because it was unclear whether vessels in the vitreous originated from the inner retina, they were excluded from the BVP index. Each section was projected onto a screen by means of a closed-circuit camera. A stereological test grid measuring 150ϫ150 mm and divided into 16-U areas was superimposed onto each image, and an automatic stage was used to advance across the entire retina by means of an unbiased counting frame. BVPs within Ն500-U areas were counted per eye.
Renin Assay
Both eyes from each rat were enucleated, and lenses and vitreous were removed. Active renin was measured in the left eye and total renin (trypsin activated) in the right eye by means of an enzyme kinetic method. 3, 13 Prorenin was derived as total minus active renin. Plasma was obtained by cardiac puncture from anesthetized rats before the rats were killed and assayed for active renin and prorenin. 3, 13 
VEGF and VEGFR-2 Gene Expression
Riboprobes were synthesized from cDNAs encoding mouse VEGF and VEGFR-2 (Dr S. Stacker, Ludwig Institute, Melbourne, Australia). The cDNAs were cloned into pGEM 4Z (Promega) and linearized with HindIII to produce antisense probes with SP6 RNA polymerase. Gene expression of VEGF and VEGFR-2 in retina were evaluated by 2 different techniques as previously described. 9 Briefly, in the first method, densitometry was performed on autoradiographs of the entire retina (nϭ6 retina per group). In the second approach, dark field images were obtained from 3-m paraffin sections of retina. The area of the inner retina occupied by autoradiographic grains was determined in 6 sections from each rat.
Statistical Analysis
Data were analyzed by ANOVA followed by a Fisher's post hoc comparison, with a value of PϽ0.05 considered statistically significant. Because retinal renin levels were not normally distributed, these data were analyzed after logarithmic transformation.
Results
Histology
In shams, BVPs in the inner retina were observed in the ILM and IPL ( Figure 1A) , and none extended into the vitreous. By contrast, in ROP rats, all eyes exhibited BVPs protruding into the vitreous from the ILM ( Figure 1B ). Numerous BVPs were observed in the IPL that appeared tortuous and branched. Hemorrhage and inflammatory cells were present in the vitreous and inner retina of some eyes. In SD and Ren-2 ROP rats treated with either lisinopril or losartan ( Figure 1 , C, D, G and H), the inner retina appeared similar to shams, although occasional vessels protruded into the vitreous of lisinopril-treated ROP rats.
Retinal Blood Vessel Profile Index
There was no significant difference in the number of BVPs per unit area of inner retina between SD and Ren-2 ROP shams ( Figure 2 ). In contrast, BVPs were increased in both Figure 1 . Three-micron paraffin sections of retina from SD (A through D) and transgenic (mRen-2)27 (E through H) rats after ROP or sham treatment. V indicates vitreous. Counterstain is hematoxylin and eosin; magnification ϫ200. Scale bar is Ϸ50 m. In sham SD ROP (A) and Ren-2 ROP (E) rats, BVPs were detected in ILM (arrow) and IPL. In SD ROP (B) and Ren-2 ROP (F) rats, numerous BVPs were detected in ILM, GCL, and IPL; some protruded into vitreous (B, arrow) and leaked red blood cells (B, asterisk). In SD ROP (C) and Ren-2 ROP (G) rats treated with lisinopril, only occasional BVPs were observed in IPL (G, arrow); none protruded into vitreous. Similarly, losartantreated SD ROP (D) and Ren-2 ROP (H) rats displayed few BVPs in ILM, GCL, and IPL (D, arrow) and none in vitreous.
SD and Ren-2 ROP groups compared with shams. Furthermore, Ren-2 ROP rats had significantly more BVPs than did SD ROP rats. Lisinopril and losartan reduced the number of BVPs in both SD ROP and Ren-2 ROP rats to the level of ROP shams.
Eye and Plasma Renin
The results are presented in the Table. In ROP shams, total renin was Ϸ6 times higher in Ren-2 than in SD rats. ROP increased retinal total renin in both SD and Ren-2 rats and was further increased with lisinopril and losartan. In both rat strains, the rise in total renin with RAS blockade was mainly due to active renin, particularly in SD ROP rats. The plasma of Ren-2 ROP sham rats contained more total renin than SD ROP shams, but it was mainly prorenin. Plasma active renin in SD and Ren-2 shams was not different, and ROP did not alter their levels. ROP increased plasma prorenin moderately in Ren-2 ROP rats. With lisinopril and losartan treatment, plasma total renin increased in both SD ROP and Ren-2 ROP rats, with SD ROP containing mainly active renin and Ren-2 ROP similar amounts of active renin and prorenin.
Quantitative In Situ Hybridization Microscopy
In shams, VEGF (Figure 3, A and B) and VEGFR-2 (not shown) expression were detected in the ILM, GCL, inner nuclear layer (INL), and retinal pigment epithelium. With ROP, the intensity of both VEGF (Figure 3 , C and D) and VEGFR-2 (not shown) mRNA were increased, and expression was also observed on vessels protruding into the vitreous. In ROP rats treated with lisinopril, labeling for VEGF (Figure 3 , E and F) and VEGFR-2 (not shown) was reduced to almost undetectable levels. Losartan did not alter the intensity or distribution of VEGF (Figure 3 , G and H) or VEGFR-2 (not shown) mRNA in ROP compared with untreated ROP rats. Quantification of optical density in autoradiographs of VEGF ( Figure 4A ) and VEGFR-2 ( Figure 4B ) and cellular expression of VEGF ( Figure 4C and VEGFR-2 ( Figure 4D ) in dark-field micrographs confirmed the qualitative assessment of probe distribution. No differences in the distribution of VEGF and VEGFR-2 expression were observed between rat strains.
Discussion
This study implicates the local ocular RAS in the pathogenesis of retinal neovascularization in ROP, as evidenced by increased retinal renin levels and prevention of vascular growth by both ACEI and AT 1 receptor blockade. In addition, in the Ren-2 rat, which phenotypically exhibits enhanced retinal active renin levels, the vessel profiles were increased more than for SD rats with induction of the hypoxia-mediated retinal injury. Of particular significance was the ability of the RAS blockers to suppress retinal neovascularization in both Ren-2 and normal SD rats. Together, these findings suggest that endogenous retinal Ang II is involved in the retinal neovascularization process.
Identification of RAS components including angiotensinogen, ACE, and renin expression within the eyes of humans, rats, and other species has provided evidence for a local RAS. [3] [4] [5] [6] [7] The detection of retinal Ang II receptors by gene expression 5 and ligand binding 6 further supports the presence of a functioning intraretinal RAS. Local production of Ang II is also suggested by the finding that retinal Ang II levels in bovine eyes are higher than in plasma. 4 Previously, we reported that renin protein exists in normal rodent and human retina mainly in the form of active renin, with localization to the Müller cell. 3 The present study provides evidence that after ROP and RAS blockade, retinal renin levels are greatly increased, with the predominant form being active renin. This rise in active eye renin is likely to represent an increase in local synthesis because active renin in plasma was not increased by ROP, and plasma would be expected to contribute Ͻ1% to ocular renin content, assuming that rat ocular blood volume is only 3.3% of total eye weight. 17 Overall, these findings are consistent with rapid tissue processing of renin and suggest, as for the kidney, 18 that RAS blockade elicits a local functional feedback on retinal renin synthesis.
Eye (Excluding Vitreous and Lens) and Plasma Renin Levels of Sprague-Dawley and Transgenic (mREN-2)27 Rats After Retinopathy of Prematurity and Sham Treatment
The finding that ocular renin content (total renin, active renin, and prorenin) in the neonatal Ren-2 rat is elevated compared with age-matched SD rats is expected on the basis of previous findings that those extrarenal tissues that normally express renin display an amplified RAS in the Ren-2 rat. 14, 15 The fact that Ren-2 and SD ROP sham rats have similar numbers of BVPs in the inner retina but that Ren-2 ROP shams phenotypically contain elevated ocular active renin could indicate that in the developing eye, renin may be stored and not important for the induction of normal vasculogenesis. Only after ROP in both Ren-2 and SD rats were BVPs increased and accompanied by a substantial rise in ocular active renin. The larger rise in BVPs in Ren-2 ROP rats compared with SD ROP rats may be explained by the release of increased amounts of stored active renin forming Ang II after the hypoxic stimulus. Whether circulating Ang II itself might be elevated and contributes to the retinal neovascularization process associated with ROP remains to be investigated, but this would seem unlikely on the basis of the observation for plasma active renin discussed above. With respect to a role for blood pressure in the stimulation of retinal blood vessel growth in the Ren-2 ROP rat, no association between hypertension and retinal neovascularization has been reported in humans 19 or the spontaneously hypertensive rat. 20 Many reports have indicated that ACEI retards the cellular and fibrointerstitial damage in conditions such as diabetic nephropathy. 13 Similar studies in the eye have been limited, although the recent report by the EUCLID study group 2 suggests that ACEI with lisinopril slows the progression of proliferative diabetic retinopathy in patients. Our present findings, together with previous observations on the retinal RAS 3 and the demonstration of angiogenic properties of Ang II, provide strong support at the cellular level for anticipating a beneficial action from RAS blockade in retinal conditions displaying neovascularization.
VEGF, a potent vessel permeability and angiogenic factor, is implicated in blood vessel growth. 21 VEGF binds to high-affinity tyrosine kinase receptors VEGFR-1 and VEGFR-2, also known as flt-1 and flk-1, respectively. 22 These two receptors have different functions, with VEGFR-2 viewed to induce alterations in cell morphology, actin reorganization, chemotaxis, and mitogenesis, whereas VEGFR-1 lacks such effects. 22 VEGF expression is induced by hypoxia and is considered to be the stimulus in neovascularizing eye pathologies such as proliferative diabetic retinopathy and ROP. 10, 21, 23 To evaluate the associated roles of the renin-angiotensin and VEGF systems in retinal neovascularization, we chose a rodent model of ROP. It is well established that exposure of neonatal animals to a high oxygen environment results in cessation of vessel growth in the inner retina, whereas subsequent exposure to room air is presumed to cause tissue hypoxia, which leads to upregulation of retinal VEGF and neovascularization. 20 Using quantitative in situ hybridization, we found that VEGF and VEGFR-2 mRNA are increased with ROP in the inner retina and in proliferating retinal vessels of both SD and Ren-2 rats. This is consistent with previous findings in ROP models 21, 23 and has been observed in the eyes of patients with proliferative diabetic Counterstain is hematoxylin and eosin; magnification ϫ150. Scale bar is Ϸ67 m. VEGF expression is detected throughout inner retina in ROP shams (A and B). With ROP (C and D), VEGF expression is increased and is evident on retinal vessels (arrow). In ROP rats treated with lisinopril (E and F), hybridization signal was not detected; in ROP rats treated with losartan (G and H), signal was intense throughout inner retina.
retinopathy. 10 The appropriateness of this model to other forms of retinal neovascularization, such as occurs in diabetes, requires further evaluation. There is increased VEGF and VEGFR-2 expression in experimental diabetic retinopathy, 24 and our previous findings suggest a decrease in retinal VEGF mRNA with ACEI in rodent diabetes. 25 The sequence and interaction of growth factor actions in retinal angiogenesis has yet to be fully explored; however, the ability of Ang II to increase VEGF mRNA in human renal glomerular mesangial cells and the finding that losartan inhibits this process 26 suggest that an increase in retinal Ang II with tissue hypoxia may be the initiating event in the rat ROP model. To our knowledge, there have been no previous studies evaluating this concept in the eye. Otani and colleagues 12 have reported that Ang II enhances VEGFR-2 mRNA and VEGF-induced cell growth in cultured bovine retinal endothelial cells. In the present study, retinal neovascularization was associated with a rise in retinal renin, VEGF, and VEGFR-2 mRNA. These findings, together with the observation that ACEI prevented neovascularization and virtually abolished VEGF and VEGFR-2 mRNA, suggest that Ang II may potentiate or initiate VEGF-induced neovascularization. Unlike Otani et al 12 and in contrast to our findings with ACEI, AT 1 receptor blockade, although preventing retinal neovascularization in ROP, failed to suppress expression of VEGF and VEGFR-2. This suggests that although Ang II appears to act as the primary effector molecule in retinal neovascularization in ROP, VEGFR-2 expression may not be primarily influenced by the AT 1 receptor but may be mediated by other pathways such as the angiotensin type 2 receptor or cytokines. It may also be possible that VEGF is not essential for neovascularization in the ROP model. Indeed, 98% inhibition of VEGF with soluble VEGF receptor chimeric proteins in a murine model of ischemic retinopathy resulted in only a partial reduction (56%) in retinal neovascularization. 27 However, a pivotal role for VEGF in the growth factor pathway leading to ROP should not be underestimated; a recent study reported that inhibition of VEGF receptor kinase activity blocked retinal neovascularization in the ROP model. 28 Our findings imply that the retinal RAS plays an important role in the pathogenesis of neovascularization in the ROP model. This information provides a rationale for the use of agents that interrupt the RAS in the prevention of proliferative retinopathy related to retinal hypoxia and possibly ischemia.
